Clinical Trials Sponsored by Glovia Co., Ltd.

Total 10283 results

Kyowa Kirin Korea Co., Ltd.

Completed

A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea

Moderate to Severe Plaque Psoriasis

Korea, Republic of
Kyowa Kirin Korea Co., Ltd.

Terminated

Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer

Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma | Phase 2 Portion : Small Cell Lung Cancer(SCLC)

Korea, Republic of
Eisai Co., Ltd.
Ono Pharmaceutical Co. Ltd

Completed

A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Japan
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9

Cervical Cancer | Papillomavirus Infections | CIN | Genital Wart | VIN

China
Sinovac Life Sciences Co., Ltd.

Completed

Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)

COVID-19

China
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Completed

Safety and Pharmacokinetics of Probucol and Cilostazol

Healthy

Korea, Republic of
Idience Co., Ltd.
National OncoVenture; IlDong Pharmaceutical Co Ltd

Completed

Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Korea, Republic of
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Completed

OPS-2071 Single and Multiple Dose Study to Investigate PK and PD Profile in Healthy Korean Male Subjects. (OPS-2071Ph1)

Healthy

Korea, Republic of
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Completed

Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder

Tourette's Disorder | Chronic Motor or Vocal Tic Disorder

Korea, Republic of
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Unknown

Observational Study of Anti-Cancer Therapy Induced Oral Mucositis in Korean Cancer Patients

Oral Mucositis

Korea, Republic of
Kyowa Kirin Korea Co., Ltd.

Recruiting

Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean Patients

FGF23-related Hypophosphataemic Rickets and Osteomalacia

Korea, Republic of
Kyowa Kirin Korea Co., Ltd.

Recruiting

Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea Patients

Hyperphosphatemia

Korea, Republic of
Sinovac Life Sciences Co., Ltd.

Recruiting

SA55 Novel Coronavirus Broad-spectrum Neutralizing Antibody Nasal Spray in Health People

COVID-19

China
Shenzhen Kexing Pharmaceutical Co., Ltd.

Recruiting

Study Evaluating SHEN26 Capsule in Patients With Mild to Moderate COVID-19

COVID-19

China
Sinovac Life Sciences Co., Ltd.

Recruiting

Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

Pneumococcal Infections

China
Kyowa Kirin Korea Co., Ltd.

Completed

An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta®)

Breast Neoplasm Female | Breast Cancer Female

Korea, Republic of
Sinovac Life Sciences Co., Ltd.

Active, not recruiting

Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine

COVID-19

China
Sinovac Life Sciences Co., Ltd.

Completed

Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents

COVID-19

China
Shenzhen Kexing Pharmaceutical Co., Ltd.

Completed

Study of SHEN26 Capsule in Patients With Mild to Moderate COVID-19

COVID-19

China
Beijing Mabworks Biotech Co., Ltd.
Betta Pharmaceuticals Co., Ltd.

Completed

mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Sinovac Life Sciences Co., Ltd.

Completed

Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19

COVID-19

China
Otsuka Pharmaceutical Co., Ltd.
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Taiwan, Korea, Republic of, Japan
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Tigermed Consulting Co., Ltd

Unknown

A Study of XY0206 in Subjects With Advanced or Metastatic Solid Tumours

Advanced or Metastatic Solid Tumours

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Tigermed Consulting Co., Ltd

Completed

Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma

HCC

China
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Completed

Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor

Solid Tumor

Korea, Republic of
Wuhan Rhegen Biotechnology Co., Ltd.
Shenzhen Rhegen Biotechnology Co., Ltd.; Wuhan Recogen Biotechnology Co., Ltd.

Withdrawn

A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster

COVID-19 Pandemic
Shanghai Chest Hospital
Geneplus-Beijing Co. Ltd.; Guangzhou Burning Rock Medical Examination Institute... and other collaborators

Unknown

A Prospective Study to Evaluate the Consistency of Next-Generation Sequencing(NGS)-Panels by Using Malignant Hydrothorax Form NSCLC

NSCLC | Malignant Hydrothorax

China
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Asthma | Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

Pooled Analysis FP_SX_250_50

Asthma

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Recruiting

Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma (AERO-PD)

Asthma

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma (ANASSA-PD)

Asthma

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Asthma | Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Recruiting

Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Recruiting

A Bioequivalence Study Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions

Asthma | Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions

Asthma | Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade (BREATH-PK250-CC)

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers (BREATH-PK500)

Bioequivalence

Greece
Tianjin Hemay Pharmaceutical Co., Ltd
Hainan General Sanyang Pharmaceutical Co., Ltd

Terminated

Study Evaluating Hemay020 In Subjects With Advanced Solid Cancer

Neoplasms，Non-Small Cell Lung Cancer

China
Sciwind Biosciences APAC CO Pty. Ltd.
Hangzhou Sciwind Biosciences Co., Ltd.; Sciwind Biosciences USA Co., Ltd.

Withdrawn

Safety and Efficacy of Inhaled XW001 For Hospitalized COVID-19 Patients Requiring Oxygen Therapy

COVID-19 Acute Respiratory Distress Syndrome

Argentina, Peru

3

Subscribe